Biosimilar Infliximab Success Paves The Way For Adalimumab In Europe

With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.